[tweetmeme source= “informa_oz” only_single=false]
The domination of the antidyslipidemic market by five top brands is set to fundamentally change over the next 10 years as novel agents fail to meet the success of their predecessors, claims a new report from independent market analyst, Datamonitor.
The top five antidyslipidemic brands: Lipitor (atorvastatin, Pfizer), Crestor (rosuvastatin, AstraZeneca), Zetia (ezetimibe, Merck), Vytorin (simvastatin and ezetimibe, Merck) and Tricor (fenofibrate, Solvay, Abbott) accounted for 74% of the market in 2009. By the end of 2019, the share commanded by these top five brands in the antidyslipidemic market is expected to fall to 35% due to the impact of generics, which will themselves account for 39% of revenues in 2019.
This drop in share for the dominant brands will take a lot of the value in the market with it. Sales value is expected to drop from $26.6 billion in 2009 down to $17 billion in 2019.
Gideon Heap, healthcare analyst at Datamonitor, comments: “The antidyslipidemic market has been performing well over the last three years. It has shown steady growth, driven by an acceleration of Crestor (rosuvastatin, AstraZeneca) sales following positive JUPITER trial results and subsequent approval in a new preventative indication.
“This growth will end by 2012 after the crucial patent expiry of Pfizer’s Liptor in the US, which will send the drug’s revenue into sharp decline and fuel the continuing genericisation of the market.”
Whilst the Datamonitor report identifies some innovative agents in the late-stage pipeline, it suggests they will face significant challenges in gaining a firm foothold in the overcrowded antidyslipidemic market.
Gideon concludes: “Ever tightening approval regulations and the safety concerns surrounding Vytorin will be a major barriers for innovative agents, suggesting that the era of branded antidyslipidemics, once over, will not return.”